Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Counterfeits: Opportunities for MEDICRIME, Challenges for IMPACT

This article was originally published in RAJ Devices

Executive Summary

Alan Chalmers reports that progress was made at a conference on the Council of Europe's proposed MEDICRIME convention, despite the controversy surrounding the World Health Organization's IMPACT initiative.

You may also be interested in...



A milestone meeting and the way forward: 10 years of Swissmedic

Alan Chalmers reports from the Swiss agency’s International Regulatory Symposium.

New Swiss requirements on submissions for generics and products with known APIs get industry thumbs up

Recently implemented Swiss rules relating to marketing submissions for generics and products with known active pharmaceutical ingredients make the application process clearer and enable regulatory timeframes to be maintained.

ICH steering committee expands global reach at 20th anniversary meeting

International Conference on Harmonisation technical working groups will now be expanded to allow active participation by experts from qualifying members of the Global Cooperation Group1. This was a key development of the ICH steering committee's meeting in Fukuoka, Japan, which took place from 6-11 November and marked the 20th anniversary of the ICH.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC096174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel